Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
The Lancet. Rheumatology|October 2, 2025
Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort studyJulien Duquesne, Louis Basseto, Charlotte Claye, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 16, 2017
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's SyndromeSimon J Bowman, Colin C Everett, John L O'Dwyer, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Rheumatology (Oxford, England)|September 22, 2014
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Rheumatology International|December 26, 2016
Physical activity but not sedentary activity is reduced in primary Sjögren's syndromeWan-Fai Ng, Ariana Miller, Simon J Bowman, et al.
Nature Metabolism|October 26, 2023
The glucose transporter 2 regulates CD8+ T cell function via environment sensingHongmei Fu, Juho Vuononvirta, Silvia Fanti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 10, 2023
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)Elena Pontarini, Elisabetta Sciacca, Farzana Chowdhury, et al.
Annals of the Rheumatic Diseases|May 22, 2024
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockadeDaniele Mauro, Xiang Lin, Elena Pontarini, et al.
Pageof 15